Analyst Reco. NeuroPace, Inc.

Equities

NPCE

US6412881053

Delayed Nasdaq Other stock markets 03:59:47 2024-06-04 pm EDT			5-day change	1st Jan Change
6.46 ^USD	0.00%		-8.89%	-37.34%

May. 13	Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating	MT
May. 08	NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating	May. 13	MT
Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16	Mar. 14	MT
JPMorgan Adjusts Price Target on NeuroPace to $17 From $9, Maintains Overweight Rating	Mar. 12	MT
Wells Fargo Increases Price Target on NeuroPace to $16 From $9, Maintains Equalweight Rating	Feb. 22	MT
Leerink Partners Initiates NeuroPace at Outperform Rating With $22 Price Target	Jan. 30	MT
Morgan Stanley Adjusts NeuroPace Price Target to $9 From $8, Maintains Equal Weight Rating	Dec. 04	MT
Morgan Stanley Adjusts Price Target on NeuroPace to $8 From $6, Maintains Equalweight Rating	Nov. 14	MT
Cantor Fitzgerald Starts Coverage on NeuroPace with Overweight Rating, $11 Price Target	Nov. 10	MT
Wells Fargo Adjusts NeuroPace Price Target to $9 From $6, Maintains Equal Weight Rating	23-10-04	MT
Morgan Stanley Upgrades NeuroPace to Equalweight From Underweight, Adjusts Price Target to $6 From $5	23-08-24	MT
Morgan Stanley Adjusts Price Target on NeuroPace to $4.50 From $2.50, Maintains Underweight Rating	23-03-03	MT
Lake Street Initiates NeuroPace at Buy With $10 Price Target	23-02-22	MT
Morgan Stanley Adjusts Price Target on NeuroPace to $2.50 From $3.50, Maintains Underweight Rating	23-01-06	MT
Morgan Stanley Adjusts NeuroPace's Price Target to $3.50 from $5.50, Maintains Underweight Rating	22-10-11	MT
Wells Fargo Adjusts NeuroPace's Price Target to $6 from $9, Keeps Equalweight Rating	22-05-13	MT
Morgan Stanley Lowers NeuroPace's Price Target to $6 From $9, Maintains Underweight Rating	22-05-13	MT
Wolfe Research Starts NeuroPace at Outperform With $13 Price Target	22-04-06	MT
Wells Fargo Adjusts NeuroPace's Price Target to $9 from $11, Keeps Equalweight Rating	22-03-11	MT
SVB Leerink Adjusts NeuroPace's Price Target to $12 from $15, Keeps Outperform Rating	22-03-11	MT
Morgan Stanley Lowers Price Target for NeuroPace to $9 From $12, Maintains Underweight Rating	22-03-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. NeuroPace, Inc.

Equities

NPCE

US6412881053

Analyst Reco.

Filters